Actinium Pharmaceuticals (ATNM) Depreciation & Amortization (CF) (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with -$434000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) changed N/A to -$434000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$229000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $173000.0 for FY2025, 12.18% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was -$434000.0 at Actinium Pharmaceuticals, down from $205000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $221000.0 in Q3 2022, with the low at -$434000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $106352.9, with a median of $180000.0 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 66.17% in 2022, then crashed 338.51% in 2023.
  • Over 5 years, Depreciation & Amortization (CF) stood at $137000.0 in 2021, then grew by 17.52% to $161000.0 in 2022, then plummeted by 338.51% to -$384000.0 in 2023, then surged by 152.6% to $202000.0 in 2024, then tumbled by 314.85% to -$434000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at -$434000.0, $205000.0, and $202000.0 for Q4 2025, Q1 2025, and Q3 2024 respectively.